{"id":"W3166905971","doi":"10.1200/jco.2021.39.15_suppl.e15581","title":"A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario; Grand River Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Health Sciences Centre; University Health Network; Ottawa Hospital; Windsor Regional Hospital; Princess Margaret Cancer Centre; University of Calgary; Queen's University; Sunnybrook Health Science Centre; Canadian Agency for Drugs and Technologies in Health; University of Toronto; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Tremelimumab; Durvalumab; Medicine; Adverse effect; Oncology; Colorectal cancer; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Cost effectiveness; Cancer; Immunotherapy; Nivolumab; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00712389,0.001703623,0.001789545,0.000880152,0.0002510487,0.0009159759,0.001505536,0.0008473413,0.00251514],"category_scores_gemma":[0.01199075,0.0006104858,0.003643502,0.0008544095,0.0004975179,0.0005281339,0.0008863367,0.001109533,0.000150281],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009887918,"about_ca_system_score_gemma":0.005068682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.07655217,"about_ca_topic_score_gemma":0.04737159,"domain_scores_codex":[0.997603,0.001786963,0.00006083748,0.0001727661,0.0001573769,0.0002190443],"domain_scores_gemma":[0.9948221,0.003565664,0.0006295622,0.0002097153,0.0003265353,0.000446336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.1227929,0.003544913,0.07246479,0.001385918,0.01435266,0.0006177803,0.0001763352,0.7262427,0.001610508,0.005260182,0.004424571,0.04712677],"study_design_scores_gemma":[0.02500408,0.02043927,0.04766838,0.0001970648,0.01001489,0.0003517019,0.0001545299,0.8888764,0.0008586677,0.002919232,0.003408404,0.0001073532],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837601,0.002892194,0.004858903,0.0009235719,0.00004018773,0.001505868,0.003888327,0.0000439853,0.002086869],"genre_scores_gemma":[0.9954169,0.0002566245,0.001721502,0.0001449832,0.00001156658,0.0004031028,0.001603564,0.000007601053,0.000434193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07655217,"threshold_uncertainty_score":0.1522132,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4701810542366179,"score_gpt":0.528333415253758,"score_spread":0.05815236101714011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}